[go: up one dir, main page]

WO2008129951A1 - Nouveau composé de pyrimidine à structure de dibenzylamine et médicament le comprenant - Google Patents

Nouveau composé de pyrimidine à structure de dibenzylamine et médicament le comprenant Download PDF

Info

Publication number
WO2008129951A1
WO2008129951A1 PCT/JP2008/057058 JP2008057058W WO2008129951A1 WO 2008129951 A1 WO2008129951 A1 WO 2008129951A1 JP 2008057058 W JP2008057058 W JP 2008057058W WO 2008129951 A1 WO2008129951 A1 WO 2008129951A1
Authority
WO
WIPO (PCT)
Prior art keywords
alkyl group
compound
lower alkyl
hydrogen atom
medicine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/JP2008/057058
Other languages
English (en)
Japanese (ja)
Inventor
Tadaaki Ohgiya
Toru Miura
Ayumu Okuda
Toshiharu Arai
Koichi Yamazaki
Taro Aoki
Katsutoshi Miyosawa
Haruki Shibata
Kimiyuki Shibuya
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Kowa Co Ltd
Original Assignee
Kowa Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to CA2683534A priority Critical patent/CA2683534C/fr
Priority to BRPI0810880A priority patent/BRPI0810880A2/pt
Priority to DK08740159.2T priority patent/DK2149563T3/en
Priority to HK10104447.9A priority patent/HK1138274B/en
Priority to AU2008241904A priority patent/AU2008241904B2/en
Priority to EA200970943A priority patent/EA017321B1/ru
Priority to NZ580777A priority patent/NZ580777A/en
Priority to EP20080740159 priority patent/EP2149563B9/fr
Priority to JP2009510828A priority patent/JP5244095B2/ja
Application filed by Kowa Co Ltd filed Critical Kowa Co Ltd
Priority to KR1020097023309A priority patent/KR101501299B1/ko
Priority to CN2008800199910A priority patent/CN101679309B/zh
Priority to PL08740159T priority patent/PL2149563T3/pl
Priority to ES08740159.2T priority patent/ES2533910T3/es
Priority to MX2009010962A priority patent/MX2009010962A/es
Publication of WO2008129951A1 publication Critical patent/WO2008129951A1/fr
Priority to IL201402A priority patent/IL201402A/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/32—One oxygen, sulfur or nitrogen atom
    • C07D239/42—One nitrogen atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/47—One nitrogen atom and one oxygen or sulfur atom, e.g. cytosine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

L'invention concerne un composé représenté par la formule générale (I) ayant un niveau élevé d'activité inhibitrice contre une protéine de transfert d'ester de cholestérol (CETP) où R1, R2, R3, R4, et R5 représentent un atome d'hydrogène, un groupe halogéno(alkyle inférieur), un groupe cyano ou analogue ; R6 représente un groupe alkyle, un groupe cycloalkyle ou analogue ; R7, R8, R9, et R10 représentent un atome d'hydrogène, un atome d'halogène, un groupe alkyle inférieur, un groupe halogéno(alkyle inférieur) ou analogue ; R11 et R12 représentent un atome d'hydrogène, un groupe alkyle inférieur, un groupe alkyle inférieur de cycloalkyle inférieur, ou analogue ; et R13 représente un atome d'hydrogène, un atome d'halogène, un groupe alcoxy inférieur ou analogue.
PCT/JP2008/057058 2007-04-13 2008-04-10 Nouveau composé de pyrimidine à structure de dibenzylamine et médicament le comprenant Ceased WO2008129951A1 (fr)

Priority Applications (15)

Application Number Priority Date Filing Date Title
JP2009510828A JP5244095B2 (ja) 2007-04-13 2008-04-10 新規なジベンジルアミン構造を有するピリミジン化合物及びこれを含有する医薬
DK08740159.2T DK2149563T3 (en) 2007-04-13 2008-04-10 Novel pyrimidine compound with dibenzylaminstruktur, and medicine comprising the compound
KR1020097023309A KR101501299B1 (ko) 2007-04-13 2008-04-10 신규한 디벤질아민 구조를 갖는 피리미딘 화합물 및 이것을 함유하는 의약
AU2008241904A AU2008241904B2 (en) 2007-04-13 2008-04-10 Novel pyrimidine compound having dibenzylamine structure and medicament comprising the same
EA200970943A EA017321B1 (ru) 2007-04-13 2008-04-10 Производные n,n-дибензил-2-аминопиримидина и лекарственные средства, их содержащие
NZ580777A NZ580777A (en) 2007-04-13 2008-04-10 Novel pyrimidine compound having dibenzylamine structure, and medicine comprising the compound
EP20080740159 EP2149563B9 (fr) 2007-04-13 2008-04-10 Nouveau composé de pyrimidine à structure de dibenzylamine et médicament le comprenant
CA2683534A CA2683534C (fr) 2007-04-13 2008-04-10 Nouveau compose de pyrimidine a structure de dibenzylamine et medicament le comprenant
HK10104447.9A HK1138274B (en) 2007-04-13 2008-04-10 Novel pyrimidine compound having dibenzylamine structure, and medicine comprising the compound
BRPI0810880A BRPI0810880A2 (pt) 2007-04-13 2008-04-10 novo composto de pirimidina com a estrutura de dibenzilamina e medicamento à base do mesmo
CN2008800199910A CN101679309B (zh) 2007-04-13 2008-04-10 具有二苄胺结构的新型嘧啶化合物和含有该化合物的药物
PL08740159T PL2149563T3 (pl) 2007-04-13 2008-04-10 Nowy związek pirymidynowy mający strukturę dibenzyloaminy i lek zawierający ten związek
ES08740159.2T ES2533910T3 (es) 2007-04-13 2008-04-10 Compuesto novedoso de pirimidina que tiene estructura de dibencilamina y medicamento que comprende el compuesto
MX2009010962A MX2009010962A (es) 2007-04-13 2008-04-10 Compuesto pirimidina novedoso que tiene estructura de dibencilamina y medicamento que comprende el mismo.
IL201402A IL201402A (en) 2007-04-13 2009-10-11 A pyrimidine compound with a dibenzylamine formulation and a drug containing it

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US91162007P 2007-04-13 2007-04-13
US60/911,620 2007-04-13

Publications (1)

Publication Number Publication Date
WO2008129951A1 true WO2008129951A1 (fr) 2008-10-30

Family

ID=39875479

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2008/057058 Ceased WO2008129951A1 (fr) 2007-04-13 2008-04-10 Nouveau composé de pyrimidine à structure de dibenzylamine et médicament le comprenant

Country Status (19)

Country Link
US (1) US7659271B2 (fr)
EP (1) EP2149563B9 (fr)
JP (2) JP5244095B2 (fr)
KR (1) KR101501299B1 (fr)
CN (1) CN101679309B (fr)
AU (1) AU2008241904B2 (fr)
BR (1) BRPI0810880A2 (fr)
CA (1) CA2683534C (fr)
DK (1) DK2149563T3 (fr)
EA (1) EA017321B1 (fr)
ES (1) ES2533910T3 (fr)
HU (1) HUE024898T2 (fr)
IL (1) IL201402A (fr)
MX (1) MX2009010962A (fr)
NZ (1) NZ580777A (fr)
PL (1) PL2149563T3 (fr)
PT (1) PT2149563E (fr)
TW (1) TWI439453B (fr)
WO (1) WO2008129951A1 (fr)

Cited By (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010061621A1 (fr) 2008-11-28 2010-06-03 興和株式会社 Méthode de fabrication d'acétate de trans-{4-[(alkylamino)méthyl]cyclohexyle}
WO2011152508A1 (fr) 2010-06-04 2011-12-08 興和株式会社 Dérivé de dibenzylamine optiquement actif et procédé pour sa préparation
WO2012011516A1 (fr) 2010-07-22 2012-01-26 興和株式会社 Procédé de production de 1-bromo-1-[3,5-bis(trifluorométhyl)phényl]éthane optiquement actif
WO2012046681A1 (fr) 2010-10-04 2012-04-12 興和株式会社 Agent capable d'inhiber l'expression d'un arnm lié au métabolisme lipidique
WO2013081087A1 (fr) * 2011-12-02 2013-06-06 興和株式会社 Procédé de préparation d'un composé optiquement actif
WO2013080999A1 (fr) 2011-11-29 2013-06-06 興和株式会社 Agent destiné à inhiber l'expression de l'arnm de npc1l1 et/ou de lipg et agent destiné à prévenir et/ou traiter l'obésité
JP2013136572A (ja) * 2011-12-02 2013-07-11 Kowa Co 光学活性ジベンジルアミン誘導体及びその製造方法
WO2013137371A1 (fr) * 2012-03-15 2013-09-19 興和株式会社 Nouveau composé pyrimidine et médicament comprenant celui-ci
WO2014017569A1 (fr) * 2012-07-26 2014-01-30 興和株式会社 Produit pharmaceutique destiné à faire baisser le taux de cholestérol ldl sanguin
JP2014520795A (ja) * 2011-07-08 2014-08-25 ノバルティス アーゲー 高トリグリセリド対象においてアテローム性動脈硬化症を治療する方法
WO2014192903A1 (fr) 2013-05-31 2014-12-04 興和株式会社 Nouvelle forme de composé pyrimidinique ayant une structure dibenzylamine
WO2017209158A1 (fr) * 2016-05-31 2017-12-07 興和株式会社 Composition médicinale

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7750019B2 (en) 2006-08-11 2010-07-06 Kowa Company, Ltd. Pyrimidine compound having benzyl(pyridylmethyl)amine structure and medicament comprising the same
US7790737B2 (en) * 2007-03-13 2010-09-07 Kowa Company, Ltd. Substituted pyrimidine compounds and their utility as CETP inhibitors
JP5319457B2 (ja) * 2008-08-25 2013-10-16 興和株式会社 新規なジベンジルアミン構造を有するピリミジン化合物及びこれを含有する医薬
EP2332923A4 (fr) * 2008-09-12 2012-08-01 Kowa Co Procédé de fabrication de la 5-[2-(méthylthio)éthoxy] et pyrimidine-2-amine
CN104628584B (zh) * 2013-11-08 2017-03-08 广州朗圣药业有限公司 一种适合工业化的高纯度达泊西汀的制备方法
KR20170087880A (ko) * 2014-11-28 2017-07-31 코와 가부시키가이샤 의약

Citations (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH1149743A (ja) 1997-02-12 1999-02-23 Japan Tobacco Inc Ｃｅｔｐ活性阻害剤として有効な化合物
WO2000017165A1 (fr) 1998-09-17 2000-03-30 Pfizer Products Inc. 4-amino substitue-2-substitue-1,2,3,4-tetrahydroquinolines utilisees comme inhibiteurs de cetp
WO2000017164A1 (fr) 1998-09-17 2000-03-30 Pfizer Products Inc. 4-carboxyamino-2-substitue-1,2,3,4-tetrahydroquinolines utilisees comme inhibiteurs de cetp
WO2000017166A1 (fr) 1998-09-17 2000-03-30 Pfizer Products Inc. 4-carboxyamino-2-methyl-1,2,3,4-tetrahydro-quinoleine utilisees comme inhibiteurs de la proteine de transfert d'ester de cholesteryle (cetp)
WO2003063868A1 (fr) 2002-02-01 2003-08-07 Pfizer Products Inc. Forme posologique a liberation controlee d'une proteine inhibant le transfert du cholesteryl ester
WO2004020393A1 (fr) 2002-08-30 2004-03-11 Japan Tobacco Inc. Compose dibenzylamine et utilisation medicinale de ce compose
WO2005095395A2 (fr) 2004-04-02 2005-10-13 Tanabe Seiyaku Co., Ltd. Derives de tetrahydronaphtyridine et procede d’elaboration desdits derives
WO2006056854A1 (fr) 2004-11-23 2006-06-01 Pfizer Products Inc. Composes et derives de dibenzyl amine
WO2006073973A2 (fr) 2004-12-31 2006-07-13 Reddy Us Therapeutics, Inc. Nouveaux dérivés de benzylamine en tant qu'inhibiteurs de cetp
WO2006098394A1 (fr) 2005-03-14 2006-09-21 Japan Tobacco Inc. Méthode pour inhiber l’absorption de lipides et l’inhibiteur de l'absorption de lipides
WO2007073934A1 (fr) * 2005-12-29 2007-07-05 Novartis Ag Derives de pyridinyle amine en tant qu’inhibiteurs de la proteine de transfert d’ester cholesterylique (cetp)
WO2007088996A1 (fr) * 2006-01-31 2007-08-09 Mitsubishi Tanabe Pharma Corporation Composés amine trisubstitués utilisés comme inhibiteurs de la protéine de transfert d'ester de cholestéryle (cetp)
WO2007126043A1 (fr) * 2006-04-27 2007-11-08 Mitsubishi Tanabe Pharma Corporation Utilisation en tant que medicaments de derives d'un acide carboxylique porteurs de cycles thiazole
WO2007128568A1 (fr) * 2006-05-10 2007-11-15 Novartis Ag Dérivés bicycliques utilisés comme inhibiteurs de cetp
WO2008018529A1 (fr) * 2006-08-11 2008-02-14 Kowa Company, Ltd. Nouveau composé pyrimidine comportant une structure benzyl(pyridylméthyl)amine et produit pharmaceutique le comprenant

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2003221376A (ja) 2001-11-21 2003-08-05 Japan Tobacco Inc Ｃｅｔｐ活性阻害剤
AU2005233160B2 (en) * 2004-04-13 2011-06-02 Merck Sharp & Dohme Corp. CETP inhibitors
US8604055B2 (en) 2004-12-31 2013-12-10 Dr. Reddy's Laboratories Ltd. Substituted benzylamino quinolines as cholesterol ester-transfer protein inhibitors
AU2006299557A1 (en) 2005-09-30 2007-04-12 Merck Sharp & Dohme Corp. Cholesteryl ester transfer protein inhibitors
CA2642130C (fr) 2005-12-28 2013-04-02 Reddy Us Therapeutics, Inc. Derives de benzylamine selectifs et leur utilite en tant qu'inhibiteurs de la proteine de transfert de l'ester de cholesterol
PE20071025A1 (es) 2006-01-31 2007-10-17 Mitsubishi Tanabe Pharma Corp Compuesto amina trisustituido
US7790737B2 (en) 2007-03-13 2010-09-07 Kowa Company, Ltd. Substituted pyrimidine compounds and their utility as CETP inhibitors

Patent Citations (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH1149743A (ja) 1997-02-12 1999-02-23 Japan Tobacco Inc Ｃｅｔｐ活性阻害剤として有効な化合物
WO2000017165A1 (fr) 1998-09-17 2000-03-30 Pfizer Products Inc. 4-amino substitue-2-substitue-1,2,3,4-tetrahydroquinolines utilisees comme inhibiteurs de cetp
WO2000017164A1 (fr) 1998-09-17 2000-03-30 Pfizer Products Inc. 4-carboxyamino-2-substitue-1,2,3,4-tetrahydroquinolines utilisees comme inhibiteurs de cetp
WO2000017166A1 (fr) 1998-09-17 2000-03-30 Pfizer Products Inc. 4-carboxyamino-2-methyl-1,2,3,4-tetrahydro-quinoleine utilisees comme inhibiteurs de la proteine de transfert d'ester de cholesteryle (cetp)
WO2003063868A1 (fr) 2002-02-01 2003-08-07 Pfizer Products Inc. Forme posologique a liberation controlee d'une proteine inhibant le transfert du cholesteryl ester
WO2004020393A1 (fr) 2002-08-30 2004-03-11 Japan Tobacco Inc. Compose dibenzylamine et utilisation medicinale de ce compose
WO2005095395A2 (fr) 2004-04-02 2005-10-13 Tanabe Seiyaku Co., Ltd. Derives de tetrahydronaphtyridine et procede d’elaboration desdits derives
WO2006056854A1 (fr) 2004-11-23 2006-06-01 Pfizer Products Inc. Composes et derives de dibenzyl amine
WO2006073973A2 (fr) 2004-12-31 2006-07-13 Reddy Us Therapeutics, Inc. Nouveaux dérivés de benzylamine en tant qu'inhibiteurs de cetp
WO2006098394A1 (fr) 2005-03-14 2006-09-21 Japan Tobacco Inc. Méthode pour inhiber l’absorption de lipides et l’inhibiteur de l'absorption de lipides
WO2007073934A1 (fr) * 2005-12-29 2007-07-05 Novartis Ag Derives de pyridinyle amine en tant qu’inhibiteurs de la proteine de transfert d’ester cholesterylique (cetp)
WO2007088996A1 (fr) * 2006-01-31 2007-08-09 Mitsubishi Tanabe Pharma Corporation Composés amine trisubstitués utilisés comme inhibiteurs de la protéine de transfert d'ester de cholestéryle (cetp)
WO2007126043A1 (fr) * 2006-04-27 2007-11-08 Mitsubishi Tanabe Pharma Corporation Utilisation en tant que medicaments de derives d'un acide carboxylique porteurs de cycles thiazole
WO2007128568A1 (fr) * 2006-05-10 2007-11-15 Novartis Ag Dérivés bicycliques utilisés comme inhibiteurs de cetp
WO2008018529A1 (fr) * 2006-08-11 2008-02-14 Kowa Company, Ltd. Nouveau composé pyrimidine comportant une structure benzyl(pyridylméthyl)amine et produit pharmaceutique le comprenant

Non-Patent Citations (7)

* Cited by examiner, † Cited by third party
Title
"Molecular Designs", vol. 7, 1990, HIROKAWA SHOTEN, article "Development of Drugs", pages: 163 - 198
"Progress in Medicine", LIFE SCIENCE MEDICA, vol. 5, 1985, pages 2157 - 2161
"Protective Groups in Organic Synthesis Third Edition", JOHN WILEY & SONS, INC.
"Protective Groups in Organic Synthesis Third Edition", JOHN WILEY & SONS, LNC.
"Protective Groups in Organic Synthesis", JOHN WILEY & SONS, INC.
CIRCULATION, vol. 105, no. 18, 2002, pages 2159 - 2165
J. LIPID. RES., vol. 43, pages 805 - 814

Cited By (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010061621A1 (fr) 2008-11-28 2010-06-03 興和株式会社 Méthode de fabrication d'acétate de trans-{4-[(alkylamino)méthyl]cyclohexyle}
US8841478B2 (en) 2008-11-28 2014-09-23 Kowa Company, Ltd. Method for preparing trans-{4-[(alkylamino) methyl]- cyclohexyl}acetic acid ester
JP5555320B2 (ja) * 2010-06-04 2014-07-23 興和株式会社 光学活性ジベンジルアミン誘導体及びその製造方法
WO2011152508A1 (fr) 2010-06-04 2011-12-08 興和株式会社 Dérivé de dibenzylamine optiquement actif et procédé pour sa préparation
EA024241B1 (ru) * 2010-06-04 2016-08-31 Кова Компани, Лтд. Оптически активное производное дибензиламина и способ его получения
US8906895B2 (en) 2010-06-04 2014-12-09 Kowa Company, Ltd. Optically active dibenzylamine derivative, and method for preparing thereof
WO2012011516A1 (fr) 2010-07-22 2012-01-26 興和株式会社 Procédé de production de 1-bromo-1-[3,5-bis(trifluorométhyl)phényl]éthane optiquement actif
WO2012046681A1 (fr) 2010-10-04 2012-04-12 興和株式会社 Agent capable d'inhiber l'expression d'un arnm lié au métabolisme lipidique
JPWO2012046681A1 (ja) * 2010-10-04 2014-02-24 興和株式会社 脂質代謝関連ｍＲＮＡの発現抑制剤
JP2014520795A (ja) * 2011-07-08 2014-08-25 ノバルティス アーゲー 高トリグリセリド対象においてアテローム性動脈硬化症を治療する方法
WO2013080999A1 (fr) 2011-11-29 2013-06-06 興和株式会社 Agent destiné à inhiber l'expression de l'arnm de npc1l1 et/ou de lipg et agent destiné à prévenir et/ou traiter l'obésité
JP2013136572A (ja) * 2011-12-02 2013-07-11 Kowa Co 光学活性ジベンジルアミン誘導体及びその製造方法
JPWO2013081087A1 (ja) * 2011-12-02 2015-04-27 興和株式会社 光学活性化合物の製造方法
WO2013081087A1 (fr) * 2011-12-02 2013-06-06 興和株式会社 Procédé de préparation d'un composé optiquement actif
WO2013137371A1 (fr) * 2012-03-15 2013-09-19 興和株式会社 Nouveau composé pyrimidine et médicament comprenant celui-ci
JPWO2013137371A1 (ja) * 2012-03-15 2015-08-03 興和株式会社 新規ピリミジン化合物及びそれらを含有する医薬
WO2014017569A1 (fr) * 2012-07-26 2014-01-30 興和株式会社 Produit pharmaceutique destiné à faire baisser le taux de cholestérol ldl sanguin
WO2014192903A1 (fr) 2013-05-31 2014-12-04 興和株式会社 Nouvelle forme de composé pyrimidinique ayant une structure dibenzylamine
KR20160014620A (ko) 2013-05-31 2016-02-11 코와 가부시키가이샤 디벤질아민 구조를 갖는 피리미딘 화합물의 신규 형태
US9682942B2 (en) 2013-05-31 2017-06-20 Kowa Company, Ltd. Form of pyrimidine compound having dibenzylamine structure
WO2017209158A1 (fr) * 2016-05-31 2017-12-07 興和株式会社 Composition médicinale

Also Published As

Publication number Publication date
JP5244095B2 (ja) 2013-07-24
EA017321B1 (ru) 2012-11-30
PL2149563T3 (pl) 2015-06-30
EA200970943A1 (ru) 2010-04-30
KR101501299B1 (ko) 2015-03-10
IL201402A0 (en) 2010-05-31
CA2683534C (fr) 2015-02-24
US20090082352A1 (en) 2009-03-26
EP2149563B9 (fr) 2015-04-22
CN101679309B (zh) 2012-02-29
JPWO2008129951A1 (ja) 2010-07-22
IL201402A (en) 2015-10-29
TW200906804A (en) 2009-02-16
ES2533910T3 (es) 2015-04-15
AU2008241904B2 (en) 2012-06-07
EP2149563A4 (fr) 2011-09-07
BRPI0810880A2 (pt) 2016-07-19
US7659271B2 (en) 2010-02-09
CN101679309A (zh) 2010-03-24
PT2149563E (pt) 2015-02-18
TWI439453B (zh) 2014-06-01
EP2149563A1 (fr) 2010-02-03
NZ580777A (en) 2011-05-27
KR20100016332A (ko) 2010-02-12
HK1138274A1 (en) 2010-08-20
DK2149563T3 (en) 2015-02-02
AU2008241904A1 (en) 2008-10-30
JP2013129678A (ja) 2013-07-04
HUE024898T2 (en) 2016-02-29
EP2149563B1 (fr) 2015-01-07
CA2683534A1 (fr) 2008-10-30
MX2009010962A (es) 2009-12-16

Similar Documents

Publication Publication Date Title
WO2008129951A1 (fr) Nouveau composé de pyrimidine à structure de dibenzylamine et médicament le comprenant
WO2008111604A1 (fr) Nouveau composé de pyrimidine ayant une structure de benzyl(hétérocycliqueméthyl)amine et produit pharmaceutique la contenant
NO20092415L (no) Heteromonocyklisk forbindelse og anvendelse derav
WO2008078678A1 (fr) Composé ester d'oxime et initiateur de photopolymérisation contenant le composé
WO2008108380A3 (fr) Composés de pyrrole
PH12013501873A1 (en) Novel imidazo-oxazine compound or salt thereof
UA90269C2 (ru) Тетрагидрохинолиновые производные и способ их получения
TW200738684A (en) Novel sulfated cyclic urea derivatives, preparation thereof and pharmaceutical use thereof as kinase inhibitors
WO2007083017A3 (fr) Nouveaux derives d'uree cyclique, leur preparation et leur utilisation pharmaceutique comme inhibiteurs de kinases
WO2008108323A1 (fr) Médicament destiné au traitement de la grippe
WO2008126889A1 (fr) Composé d'hydrazide et agent contrôlant l'arthropode nocif le contenant
WO2008140066A3 (fr) Nouveaux composés
WO2009054439A1 (fr) Inhibiteur de la production de pai-1
WO2008126901A1 (fr) Composé hétérocyclique contenant de l'azote et composition pharmaceutique le contenant
WO2005095395A3 (fr) Derives de tetrahydronaphtyridine et procede d’elaboration desdits derives
PH12012502033A1 (en) Pesticidal composition and its use
SG196785A1 (en) 3,4,4a,10b-tetrahydro-1h-thiopyrano-[4, 3-c] isoquinoline derivatives
WO2008003854A3 (fr) Derives de 2-benzoyl-imidazopyridines, leur preparation et leur application en therapeutique
MX343077B (es) Nuevo derivado de octahidrotienoquinolina, composicion farmaceutica que comprende el derivado, y uso de los mismos.
MX2007003872A (es) Nuevos derivados bis-azaindolicos, preparacion y su uso farmaceutico de los mismos como inhibidores de cinasas.
NZ595890A (en) Pyrazole compound
WO2011012620A3 (fr) Traitements pour l'alkylation de pyrazoles
MX342390B (es) Proceso para preparar 3-haloalquilpirazoles.
MX344503B (es) Composicion para el control de plagas y metodo para controlar plagas.
MY145368A (en) Aminoquinoxaline compounds and polyaminoquinoxaline compounds, and use thereof

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 200880019991.0

Country of ref document: CN

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 08740159

Country of ref document: EP

Kind code of ref document: A1

ENP Entry into the national phase

Ref document number: 2683534

Country of ref document: CA

Ref document number: 2009510828

Country of ref document: JP

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: MX/A/2009/010962

Country of ref document: MX

WWE Wipo information: entry into national phase

Ref document number: 201402

Country of ref document: IL

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 580777

Country of ref document: NZ

WWE Wipo information: entry into national phase

Ref document number: 2008241904

Country of ref document: AU

ENP Entry into the national phase

Ref document number: 20097023309

Country of ref document: KR

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 2008740159

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 6666/CHENP/2009

Country of ref document: IN

Ref document number: 200970943

Country of ref document: EA

ENP Entry into the national phase

Ref document number: 2008241904

Country of ref document: AU

Date of ref document: 20080410

Kind code of ref document: A

REG Reference to national code

Ref country code: BR

Ref legal event code: B01E

Ref document number: PI0810880

Country of ref document: BR

Free format text: ESCLARECA A DIVERGENCIA ENTRE O NOME DO INVENTOR NOMEADO NO FORMULARIO 1.03 NA PETICAO NO 020090095644 DE 09/10/2009 TORU MIUKA E O CONSTANTE NA PUBLICACAO INTERNACIONAL WO 2008/129951 DE 30/10/2008 MIURA, TORU . ADEMAIS, APRESENTE O COMPLEMENTO DO TEXTO EM PORTUGUES, ADAPTADO A NORMA VIGENTE, DO PEDIDO CONFORME DEPOSITO INTERNACIONAL INICIAL (RELATORIO DESCRITIVO, RESUMO E DESENHOS) CONFORME DETERMINA O ATO NORMATIVO 128/97 NO ITEM 9.2.1.

ENP Entry into the national phase

Ref document number: PI0810880

Country of ref document: BR

Kind code of ref document: A2

Effective date: 20091009